A rre company.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases.
Living with Fabry
“It has been 15 years since a treatment was approved in the U.S. for people with Fabry disease. We’re excited to have a second option available for some people living with Fabry Disease.”
Founder & President
National Fabry Disease Foundation
Inventive science is at the core
of our technology platforms.
Living with Pompe
News & Announcements
October 11, 2018
October 8, 2018
Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
October 5, 2018
Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society
October 2, 2018
Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society
September 26, 2018
A Rare Company – Persistence & Resilience
At Amicus Therapeutics, we believe that we should never give up on our mission to help people with rare diseases. This video in our #RareCompany series talks about the importance of persistence & resilience in our daily work of developing medicines and serving the rare disease community.
A Rare Company – Extraordinary Patient Focus
At Amicus, patient-centricity is in our DNA. See how our commitment to patients goes further than just our medicines and expands out to the rare disease community at large.